|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|||
|
Exenatide Versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes |
Exenatida en Comparación con Insulina Glargina en Pacientes con Diabetes Tipo 2 con Control Subóptimo |
||
|
exenatida, insulina glargina, diabetes tipo 2, control glucémico, peso |
exenatide, insulin glargine, type 2 diabetes, glycemic control, weight |
||
|
Heine RJ, Van Gaal LF, Brodows RG |
RJ Heine, VU University Medical Center 1007 MB Amsterdam Países Bajos |
||
|
Eli Lilly and Company; Amylin Pharmaceuticals. |
Johns, Mihm, Widel y Brodows (Eli Lilly and Company). |
||
|
VU University Medical Center |
|||
|
ReSIIC editado en las
especialidades: |
|||
|
|
|
|
|
Sociedad Iberoamericana de Información Científica (SIIC)
|